Symbols / IBO $0.44 +0.50%
IBO Chart
About
Impact BioMedical Inc. discovers, develops, and commercializes products and technologies to address unmet needs in human healthcare and wellness for specialty biopharmaceuticals, antivirals, antimicrobials, consumer healthcare, and wellness products in the United States. The company provides Linebacker, a platform of small molecule electrophilically enhanced polyphenol compounds with application in oncology, inflammatory disorders, and neurology; and Laetose technology that is derived from a unique combination of sugar and inositol, which can inhibit the inflammatory and metabolic response of sugar alone. It also develops functional fragrance formulation, a suite of functional fragrances containing specialized botanical ingredients with application as an antimicrobial, and as an additive in insect repellents, detergents, lotions, shampoo, fabrics, and other substances. In addition, the company develops Equivir/Equivir G technology, a novel blend of polyphenols, which have demonstrated antiviral effects for use as health supplements and medications. Further, it is developing 3F (functional fragrance formulation), a formulation of botanical ingredients. Impact BioMedical Inc. was incorporated in 2018 and is based in Houston, Texas. Impact BioMedical Inc. operates as a subsidiary of DSS, Inc.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 46.14M |
| Enterprise Value | 50.49M | Income | -11.84M | Sales | 32.00K |
| Book/sh | 0.12 | Cash/sh | 3000.00 | Dividend Yield | — |
| Payout | 0.00% | Employees | — | IPO | — |
| P/E | — | Forward P/E | — | PEG | — |
| P/S | 1441.81 | P/B | 3.64 | P/C | — |
| EV/EBITDA | -16.16 | EV/Sales | 1577.88 | Quick Ratio | 0.01 |
| Current Ratio | 0.35 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -3.94 | EPS next Y | — | EPS Growth | — |
| Revenue Growth | — | Earnings | — | ROA | -14.16% |
| ROE | -104.16% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | -165.43% | Profit Margin | 0.00% | Shs Outstand | 104.62M |
| Shs Float | 106.83M | Short Float | 1.32% | Short Ratio | 2.92 |
| Short Interest | — | 52W High | 6.17 | 52W Low | 0.36 |
| Beta | — | Avg Volume | 4.44M | Volume | 226.53K |
| Target Price | — | Recom | None | Prev Close | $0.44 |
| Price | $0.44 | Change | 0.50% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$0.44
Latest analyst target
3. DCF / Fair value
$-0.26
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.44
Low
—
High
—
Mean
—
News
RSS: Latest IBO news- Why Is Impact BioMedical Stock (IBO) Up Today? - TipRanks hu, 05 Mar 2026 08
- Impact Biomedical (IBO) Stock Jumps Over 86% After Hours — Here's Why - Benzinga Wed, 04 Mar 2026 08
- IBO Stock Spikes Pre-Market: Retail Traders Pile Into Biotech Penny Stock After Merger Update - Stocktwits hu, 05 Mar 2026 08
- Market Movers | Winners: TVGN, TPET, IBO | Losers: IMG, MDCX, SES - Trefis hu, 05 Mar 2026 08
- Impact BioMedical (IBO) Stock Surges 115% After Merger Amendment Extends Deadline to July 2026 - MEXC hu, 05 Mar 2026 16
- Global Pharma Merger: Dr Ashleys Takes Over NYSE-Listed Impact BioMedical to Fast-Track Drug Patents - Stock Titan Mon, 23 Jun 2025 07
- Announcement - In relation to the matter of IBO Technology Company Limited (In Liquidation) (incorporated in the Cayman Islands with limited liability) (Stock Code: 2708) Cancellation of listing - hkex.com.hk Wed, 03 Dec 2025 08
- Impact Biomedical stock soars after merger deal with Dr Ashleys - Investing.com Mon, 23 Jun 2025 07
- Why Impact Biomedical Inc. (IBO) Surged On Thursday? - Yahoo Finance Fri, 21 Mar 2025 07
- IBO Forecast — Price Prediction for 2026. Should I Buy IBO? - Intellectia AI Mon, 19 May 2025 08
- IBO Stock Price, News & Analysis - Stock Titan Fri, 25 Apr 2025 02
- Why did IBO stock surge 65% in pre-market today? - MSN Sun, 08 Mar 2026 05
- Does Universal Ibogaine (CVE:IBO) Have A Healthy Balance Sheet? - simplywall.st hu, 12 Jun 2025 07
- Impact BioMedical Amends Merger Terms and Extends Deadline - TipRanks Wed, 04 Mar 2026 08
- 12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga Mon, 02 Mar 2026 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 161000 | 88006 | — | Sale at price 0.54 - 0.55 per share. | DSS INC. | Beneficial Owner of more than 10% of a Class of Security | — | 2025-05-27 00:00:00 | D |
| 1 | 1689693 | 996397 | — | Sale at price 0.46 - 0.96 per share. | CHAN HENG FAI AMBROSE | Director and Beneficial Owner of more than 10% of a Class of Security | — | 2025-04-04 00:00:00 | I |
| 2 | 890800 | 845013 | — | Sale at price 0.95 per share. | DSS INC. | Beneficial Owner of more than 10% of a Class of Security | — | 2025-04-04 00:00:00 | D |
| 3 | 351555 | 174020 | — | Sale at price 0.50 per share. | CHAN HENG FAI AMBROSE | Director | — | 2025-04-03 00:00:00 | I |
| 4 | 2526918 | 2199273 | — | Sale at price 0.82 - 1.03 per share. | CHAN HENG FAI AMBROSE | Director and Beneficial Owner of more than 10% of a Class of Security | — | 2025-04-01 00:00:00 | I |
| 5 | 605620 | 2726169 | — | Sale at price 2.20 - 4.96 per share. | DSS INC. | Beneficial Owner of more than 10% of a Class of Security | — | 2025-03-27 00:00:00 | D/I |
| 6 | 53300 | 110880 | — | Sale at price 2.08 - 2.90 per share. | DSS INC. | Beneficial Owner of more than 10% of a Class of Security | — | 2025-03-20 00:00:00 | I |
| 7 | 200 | 416 | — | Purchase at price 2.08 per share. | DSS INC. | Beneficial Owner of more than 10% of a Class of Security | — | 2025-03-20 00:00:00 | I |
| 8 | 500 | 1129 | — | Purchase at price 2.26 per share. | HEUSZEL FRANK D. | Chief Executive Officer | — | 2024-12-05 00:00:00 | D |
| 9 | 500 | 1305 | — | Purchase at price 2.61 per share. | HEUSZEL FRANK D. | Chief Executive Officer | — | 2024-11-27 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -5.32M | 0.00 | -323.90K | -323.90K |
| TaxRateForCalcs | 0.21 | 0.00 | 0.08 | 0.08 |
| NormalizedEBITDA | 2.80M | -2.84M | -2.20M | -2.20M |
| TotalUnusualItems | -25.36M | 0.00 | -4.10M | -4.10M |
| TotalUnusualItemsExcludingGoodwill | -25.36M | 0.00 | -4.10M | -4.10M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -24.71M | -4.34M | -7.05M | -7.05M |
| ReconciledDepreciation | 1.12M | 1.12M | 1.11M | 1.11M |
| EBITDA | -22.55M | -2.84M | -6.30M | -6.30M |
| EBIT | -23.67M | -3.96M | -7.41M | -7.41M |
| NetInterestIncome | -1.05M | -431.00K | -438.00K | -438.00K |
| InterestExpense | 1.06M | 444.00K | 462.00K | 462.00K |
| InterestIncome | 13.00K | 13.00K | 24.00K | 24.00K |
| NormalizedIncome | -4.68M | -4.34M | -3.27M | -3.27M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -24.71M | -4.34M | -7.05M | -7.05M |
| TotalExpenses | 3.40M | 4.03M | 3.45M | 3.45M |
| RentExpenseSupplemental | 32.00K | 0.00 | ||
| TotalOperatingIncomeAsReported | -28.75M | -4.03M | -3.40M | -3.40M |
| DilutedAverageShares | 10.76M | 60.25M | 11.50M | 60.25M |
| BasicAverageShares | 10.76M | 60.25M | 11.50M | 11.50M |
| DilutedEPS | -2.30 | -0.07 | -0.61 | -0.61 |
| BasicEPS | -2.30 | -0.07 | -0.61 | -0.61 |
| DilutedNIAvailtoComStockholders | -24.71M | -4.34M | -7.05M | -7.05M |
| NetIncomeCommonStockholders | -24.71M | -4.34M | -7.05M | -7.05M |
| NetIncome | -24.71M | -4.34M | -7.05M | -7.05M |
| MinorityInterests | 62.00K | 71.00K | 204.00K | 204.00K |
| NetIncomeIncludingNoncontrollingInterests | -24.77M | -4.41M | -7.25M | -7.25M |
| NetIncomeContinuousOperations | -24.77M | -4.41M | -7.25M | -7.25M |
| TaxProvision | 33.00K | 0.00 | -621.00K | -621.00K |
| PretaxIncome | -24.74M | -4.41M | -7.88M | -7.88M |
| OtherIncomeExpense | -20.29M | 52.00K | -4.03M | -4.03M |
| OtherNonOperatingIncomeExpenses | 5.07M | 52.00K | 66.00K | 66.00K |
| SpecialIncomeCharges | -25.36M | 0.00 | -4.10M | -4.10M |
| WriteOff | 0.00 | 4.10M | 4.10M | |
| ImpairmentOfCapitalAssets | 25.36M | 0.00 | ||
| NetNonOperatingInterestIncomeExpense | -1.05M | -431.00K | -438.00K | -438.00K |
| InterestExpenseNonOperating | 1.06M | 444.00K | 462.00K | 462.00K |
| InterestIncomeNonOperating | 13.00K | 13.00K | 24.00K | 24.00K |
| OperatingIncome | -3.40M | -4.03M | -3.40M | -3.40M |
| OperatingExpense | 3.40M | 4.03M | 3.45M | 3.45M |
| OtherOperatingExpenses | 171.00K | 119.00K | 68.00K | 68.00K |
| DepreciationAmortizationDepletionIncomeStatement | 1.12M | 1.12M | 1.11M | 1.11M |
| DepreciationAndAmortizationInIncomeStatement | 1.12M | 1.12M | 1.11M | 1.11M |
| Amortization | 1.12M | 1.11M | 1.11M | |
| AmortizationOfIntangiblesIncomeStatement | 1.12M | 1.11M | 1.11M | |
| ResearchAndDevelopment | 278.00K | 1.69M | 1.23M | 1.23M |
| SellingGeneralAndAdministration | 1.83M | 1.10M | 1.05M | 1.05M |
| SellingAndMarketingExpense | 633.00K | 65.00K | 325.00K | 325.00K |
| GeneralAndAdministrativeExpense | 1.20M | 1.04M | 1.05M | 1.05M |
| OtherGandA | 1.16M | 1.04M | 1.05M | 1.05M |
| RentAndLandingFees | 32.00K | 0.00 | ||
| TotalRevenue | 0.00 | 0.00 | 50.00K | 50.00K |
| OperatingRevenue | 0.00 | 0.00 | 50.00K | 50.00K |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 11.50M | 11.50M | 11.50M | 11.50M |
| ShareIssued | 11.50M | 11.50M | 11.50M | 11.50M |
| NetDebt | 6.88M | 12.07M | 9.99M | 12.48M |
| TotalDebt | 8.88M | 12.07M | 9.99M | 12.52M |
| TangibleBookValue | -13.61M | -18.85M | -15.57M | -9.63M |
| InvestedCapital | 13.08M | 37.24M | 39.55M | 49.13M |
| WorkingCapital | -7.34M | -12.80M | -10.47M | -12.36M |
| NetTangibleAssets | -13.55M | -18.79M | -15.57M | -9.63M |
| CommonStockEquity | 4.20M | 25.16M | 29.56M | 36.61M |
| PreferredStockEquity | 60.00K | 60.00K | ||
| TotalCapitalization | 4.26M | 25.22M | 29.56M | 36.61M |
| TotalEquityGrossMinorityInterest | 7.24M | 28.26M | 32.67M | 39.92M |
| MinorityInterest | 2.98M | 3.04M | 3.11M | 3.31M |
| StockholdersEquity | 4.26M | 25.22M | 29.56M | 36.61M |
| RetainedEarnings | -37.67M | -12.96M | -8.62M | -1.57M |
| AdditionalPaidInCapital | 41.86M | 38.11M | 38.11M | 38.06M |
| CapitalStock | 71.00K | 70.00K | 70.00K | 125.00K |
| CommonStock | 11.00K | 10.00K | 70.00K | 125.00K |
| PreferredStock | 60.00K | 60.00K | 0.00 | |
| TotalLiabilitiesNetMinorityInterest | 13.05M | 16.37M | 13.83M | 16.50M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 3.27M | 3.23M | 3.23M | 3.86M |
| NonCurrentDeferredLiabilities | 3.27M | 3.23M | 3.23M | 3.86M |
| NonCurrentDeferredTaxesLiabilities | 3.27M | 3.23M | 3.23M | 3.86M |
| CurrentLiabilities | 9.79M | 13.14M | 10.59M | 12.64M |
| CurrentDebtAndCapitalLeaseObligation | 8.88M | 12.07M | 9.99M | 12.52M |
| CurrentDebt | 8.88M | 12.07M | 9.99M | 12.52M |
| CurrentNotesPayable | 8.88M | 12.07M | 9.99M | 12.52M |
| PayablesAndAccruedExpenses | 907.00K | 1.06M | 602.00K | 121.00K |
| CurrentAccruedExpenses | 194.00K | 230.00K | 63.00K | 6.00K |
| Payables | 713.00K | 832.00K | 539.00K | 115.00K |
| AccountsPayable | 713.00K | 832.00K | 539.00K | 115.00K |
| TotalAssets | 20.29M | 44.63M | 46.50M | 56.42M |
| TotalNonCurrentAssets | 17.84M | 44.30M | 46.38M | 56.14M |
| OtherNonCurrentAssets | 782.00K | 4.82M | ||
| NonCurrentNoteReceivables | 17.00K | 0.00 | 190.00K | 5.08M |
| InvestmentsAndAdvances | 0.00 | 782.00K | 4.82M | |
| OtherInvestments | 0.00 | 782.00K | ||
| LongTermEquityInvestment | 782.00K | 4.82M | ||
| InvestmentsInOtherVenturesUnderEquityMethod | 782.00K | 4.82M | ||
| GoodwillAndOtherIntangibleAssets | 17.81M | 44.01M | 45.13M | 46.24M |
| OtherIntangibleAssets | 17.81M | 18.92M | 20.03M | 21.15M |
| Goodwill | 0.00 | 25.09M | 25.09M | 25.09M |
| NetPPE | 17.00K | 287.00K | 276.00K | 0.00 |
| AccumulatedDepreciation | -13.00K | -6.00K | 0.00 | 0.00 |
| GrossPPE | 30.00K | 293.00K | 276.00K | 0.00 |
| ConstructionInProgress | 0.00 | 263.00K | 251.00K | 0.00 |
| MachineryFurnitureEquipment | 30.00K | 30.00K | 25.00K | 0.00 |
| CurrentAssets | 2.45M | 332.00K | 122.00K | 287.00K |
| OtherCurrentAssets | 104.00K | 1.00K | ||
| PrepaidAssets | 265.00K | 0.00 | 61.00K | 43.00K |
| Receivables | 184.00K | 331.00K | 16.00K | 197.00K |
| OtherReceivables | 128.00K | |||
| NotesReceivable | 184.00K | 203.00K | 16.00K | 197.00K |
| CashCashEquivalentsAndShortTermInvestments | 2.00M | 1.00K | 2.00K | 46.00K |
| CashAndCashEquivalents | 2.00M | 1.00K | 2.00K | 46.00K |
| CashFinancial | 2.00M | 1.00K |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -3.92M | -2.87M | -2.52M | -2.52M |
| IssuanceOfDebt | 2.19M | 2.87M | 2.55M | 2.55M |
| IssuanceOfCapitalStock | 3.73M | 0.00 | ||
| CapitalExpenditure | -18.00K | -276.00K | -276.00K | |
| EndCashPosition | 2.00M | 1.00K | 2.00K | 2.00K |
| BeginningCashPosition | 1.00K | 2.00K | 46.00K | 46.00K |
| ChangesInCash | 2.00M | -1.00K | -44.00K | -44.00K |
| FinancingCashFlow | 5.92M | 2.87M | 2.55M | 2.55M |
| CashFlowFromContinuingFinancingActivities | 5.92M | 2.87M | 2.55M | 2.55M |
| NetCommonStockIssuance | 3.73M | 0.00 | ||
| CommonStockIssuance | 3.73M | 0.00 | ||
| NetIssuancePaymentsOfDebt | 2.19M | 2.87M | 2.55M | 2.55M |
| NetShortTermDebtIssuance | 2.19M | 2.87M | 2.55M | 2.55M |
| ShortTermDebtIssuance | 2.19M | 2.87M | 2.55M | 2.55M |
| InvestingCashFlow | 2.00K | -15.00K | -349.00K | -349.00K |
| CashFlowFromContinuingInvestingActivities | 2.00K | -15.00K | -349.00K | -349.00K |
| NetOtherInvestingChanges | 2.00K | 3.00K | -8.00K | -8.00K |
| NetInvestmentPurchaseAndSale | 0.00 | -65.00K | -65.00K | |
| PurchaseOfInvestment | 0.00 | -65.00K | -65.00K | |
| NetPPEPurchaseAndSale | 0.00 | -18.00K | -276.00K | -276.00K |
| PurchaseOfPPE | 0.00 | -18.00K | -276.00K | -276.00K |
| OperatingCashFlow | -3.92M | -2.85M | -2.24M | -2.24M |
| CashFlowFromContinuingOperatingActivities | -3.92M | -2.85M | -2.24M | -2.24M |
| ChangeInWorkingCapital | -608.00K | 436.00K | 421.00K | 421.00K |
| ChangeInPayablesAndAccruedExpense | -471.00K | 460.00K | 481.00K | 481.00K |
| ChangeInAccruedExpense | -35.00K | 167.00K | 57.00K | 57.00K |
| ChangeInPayable | -436.00K | 293.00K | 424.00K | 424.00K |
| ChangeInAccountPayable | -436.00K | 293.00K | 424.00K | 424.00K |
| ChangeInPrepaidAssets | -265.00K | 104.00K | -60.00K | -60.00K |
| ChangeInReceivables | 128.00K | -128.00K | 0.00 | 0.00 |
| OtherNonCashItems | -5.07M | |||
| StockBasedCompensation | 19.00K | 0.00 | ||
| AssetImpairmentCharge | 25.36M | 0.00 | 4.10M | 4.10M |
| DeferredTax | 33.00K | 0.00 | -621.00K | -621.00K |
| DeferredIncomeTax | 33.00K | 0.00 | -621.00K | -621.00K |
| DepreciationAmortizationDepletion | 1.12M | 1.12M | 1.11M | 1.11M |
| DepreciationAndAmortization | 1.12M | 1.12M | 1.11M | 1.11M |
| AmortizationCashFlow | 1.11M | 1.11M | ||
| AmortizationOfIntangibles | 1.11M | 1.11M | ||
| NetIncomeFromContinuingOperations | -24.77M | -4.41M | -7.25M | -7.25M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for IBO
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|